Literature DB >> 33567428

Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.

Yorinari Ochiai1, Toshiro Iizuka1, Yoshio Hoshihara1,2, Yugo Suzuki1, Junnosuke Hayasaka1, Kosuke Nomura1, Masami Tanaka1, Hiroyuki Odagiri1, Satoshi Yamashita1, Akira Matsui1, Daisuke Kikuchi1, Masaki Ueno3, Harushi Udagawa3, Shu Hoteya1.   

Abstract

BACKGROUND: Refractory reflux esophagitis (RRE), unresponsive to conventional proton-pump inhibitors (PPIs), is a complication in esophagectomy with gastric pull-up. Vonoprazan (VPZ), a novel potassium-competitive acid blocker, has been available in Japan since 2015. Here, we investigated the efficacy of VPZ on PPI-resistant RRE after esophagectomy with gastric pull-up.
METHODS: This was a single-center retrospective study. We used the revised Los Angeles (r-LA) classification based on the Los Angeles classification and the modified Los Angeles classification to evaluate abnormal forms of mucosal breaks such as lateral spreading consistently. Patients who underwent esophagectomy with gastric pull-up and had RRE grade B-D as per the r-LA classification, despite using standard-dose PPIs or double dose of rabeprazole, were included. Sixteen patients who switched to VPZ (20 mg/day) and 14 patients who continued PPIs were assigned to the VPZ and PPI groups, respectively. Endoscopic observations were reviewed by 3 endoscopists using the r-LA classification to ensure consistent diagnosis, while the treatment arm and patient information were blinded to evaluators. We defined mucosal breaks that improved by at least one grade after treatment as improved mucosa and recovery to grade M or N as mucosal healing.
RESULTS: The percentage of patients with improved mucosa in the VPZ and PPI groups was 81.3 and 14.3%, respectively (p < 0.001). The rate of mucosal healing was 68.8 and 7.1%, respectively (p = 0.001).
CONCLUSION: VPZ significantly improved PPI-resistant RRE after esophagectomy with gastric pull-up.
© 2021 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acid reflux; Esophagectomy; Proton-pump inhibitor; Reflux esophagitis; Vonoprazan

Mesh:

Substances:

Year:  2021        PMID: 33567428      PMCID: PMC8686710          DOI: 10.1159/000515146

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  19 in total

1.  1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.

Authors:  Yasunobu Hori; Akio Imanishi; Jun Matsukawa; Yasuhiro Tsukimi; Haruyuki Nishida; Yasuyoshi Arikawa; Keizo Hirase; Masahiro Kajino; Nobuhiro Inatomi
Journal:  J Pharmacol Exp Ther       Date:  2010-07-12       Impact factor: 4.030

2.  The endoscopic assessment of esophagitis: a progress report on observer agreement.

Authors:  D Armstrong; J R Bennett; A L Blum; J Dent; F T De Dombal; J P Galmiche; L Lundell; M Margulies; J E Richter; S J Spechler; G N Tytgat; L Wallin
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

3.  Columnar epithelium morphology after esophagectomy: clinical insight into the development of Barrett's esophagus.

Authors:  Toshiro Iizuka; Yugo Suzuki; Daisuke Kikuchi; Yoshio Hoshihara; Yu Ohkura; Masaki Ueno
Journal:  Esophagus       Date:  2020-05-07       Impact factor: 4.230

Review 4.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.

Authors:  T Ishizaki; Y Horai
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

5.  The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.

Authors:  D R Scott; K B Munson; E A Marcus; N W G Lambrecht; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2015-09-30       Impact factor: 8.171

Review 6.  Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

Authors:  U Klotz
Journal:  Int J Clin Pharmacol Ther       Date:  2006-07       Impact factor: 1.366

Review 7.  [Endoscopic findings of GERD].

Authors:  Yoshio Hoshihara
Journal:  Nihon Rinsho       Date:  2004-08

8.  Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.

Authors:  T Kagami; S Sahara; H Ichikawa; T Uotani; M Yamade; M Sugimoto; Y Hamaya; M Iwaizumi; S Osawa; K Sugimoto; H Miyajima; T Furuta
Journal:  Aliment Pharmacol Ther       Date:  2016-03-18       Impact factor: 8.171

9.  Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy.

Authors:  Manabu Okuyama; Satoru Motoyama; Kiyotomi Maruyama; Kenji Sasaki; Yusuke Sato; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2008-02       Impact factor: 3.352

10.  Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

Authors:  N J Bell; D Burget; C W Howden; J Wilkinson; R H Hunt
Journal:  Digestion       Date:  1992       Impact factor: 3.216

View more
  1 in total

Review 1.  Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review.

Authors:  Décio Chinzon; Joaquim Prado P Moraes-Filho; Gerson Domingues; Juliana Leite Soares Guedes; Cláudia Yang Santos; Schlioma Zaterka
Journal:  Prz Gastroenterol       Date:  2021-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.